Hepatocellular Carcinoma

• CLINICAL_TRIALS trial_result · 2022-06-16
  Clinical Trial Update: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification [Phase 3]

  A Phase 3 trial comparing hepatic arterial infusion with Apatinib and Camrelizumab versus Apatinib and Camrelizumab for C-staged hepatocellu…

• CLINICAL_TRIALS trial_result · 2022-06-09
  Clinical Trial Update: Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC [Phase 2]

  Phase 2 trial update investigating anti-PD-1 antibody in combination with DEB-TACE for hepatocellular carcinoma (BCLC A/B).

• CLINICAL_TRIALS trial_result · 2022-05-31
  Clinical Trial Update: Efficacy and Safety of T+A+RAD in HCC [Phase 2]

  Phase 2 clinical trial update on efficacy and safety of T+A+RAD in hepatocellular carcinoma.

• CLINICAL_TRIALS trial_result · 2022-05-25
  Clinical Trial Update: RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection [Phase 4]

  A Phase 4 clinical trial evaluating different nucleoside analogue regimens on prognosis after curative resection in HBV-related hepatocellul…

• CLINICAL_TRIALS trial_result · 2022-05-24
  Clinical Trial Update: Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma [Phase 3]

  Phase 3 trial comparing hepatic arterial infusion raltetrexed with oxaliplatin (SALOX) vs FOLFOX in advanced hepatocellular carcinoma is ong…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-05-19
  Clinical Trial Update: TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer [Phase 3]

  Phase 3 trial comparing TACE plus Lenvatinib versus TACE followed by Lenvatinib in hepatocellular carcinoma (liver cancer). Status is unknow…

• CLINICAL_TRIALS trial_result · 2022-05-11
  Clinical Trial Update: Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation [Phase 2]

  Phase 2 trial evaluating bevacizumab biosimilar with FOLFOX4 for recurrent hepatocellular carcinoma after liver transplantation.

• CLINICAL_TRIALS trial_result · 2022-05-05
  Clinical Trial Update: A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) [Phase 2]

  Phase 2 trial assessing hepatic arterial infusion with bevacizumab and sintilimab for unresectable hepatocellular carcinoma (BCLC A-stage).

• CLINICAL_TRIALS trial_result · 2022-05-04
  Clinical Trial Update: TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection [Phase 2]

  Phase 2 trial evaluating TQB2450 plus anlotinib as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence after surgical r…

• CLINICAL_TRIALS trial_result · 2022-05-03
  Clinical Trial Update: HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma [Phase 2]

  Phase 2 clinical trial update for HLX07 combination therapy in patients with advanced hepatocellular carcinoma.

• CLINICAL_TRIALS trial_result · 2022-05-02
  Clinical Trial Update: Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor [Phase 1, Phase 2]

  Phase 1/2 trial update evaluating NKT cell infusion for advanced solid tumors, with indications including non-small cell lung cancer and gas…

• CLINICAL_TRIALS trial_result · 2022-04-27
  Clinical Trial Update: TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer [Phase 2, Phase 3]

  Phase 2/Phase 3 trial comparing transarterial chemoembolization (TACE) alone versus TACE combined with stereotactic body radiotherapy (SBRT)…

• CLINICAL_TRIALS trial_result · 2022-04-15
  Clinical Trial Update: Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma [Phase 2]

  This update reports termination of a Phase 2 randomized study evaluating TAC-101 in combination with transcatheter arterial chemoembolizatio…

• CLINICAL_TRIALS trial_result · 2022-04-14
  Clinical Trial Update: Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples [Phase 2]

  Phase 2 clinical trial update for Surufatinib in advanced hepatocellular carcinoma based on single-cell sequencing analyses.

• CLINICAL_TRIALS trial_result · 2022-04-05
  Clinical Trial Update: HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection [Phase 2]

  Phase 2 clinical trial evaluating HAIC combined with Anlotinib and TQB2450 as adjuvant therapy for hepatocellular carcinoma patients at high…

• CLINICAL_TRIALS trial_result · 2022-04-04
  Clinical Trial Update: Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) [Phase 2]

  Phase 2 study of pembrolizumab as monotherapy in advanced hepatocellular carcinoma (MK-3475-224/KEYNOTE-224) has completed with results post…

• CLINICAL_TRIALS trial_result · 2022-03-31
  Clinical Trial Update: MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma [Phase 1, Phase 2]

  Phase 1/2 study comparing MLN0128 to sorafenib in advanced or metastatic hepatocellular carcinoma was terminated with results posted.

• CLINICAL_TRIALS trial_result · 2022-03-31
  Clinical Trial Update: Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors [Phase 2]

  Phase 2 trial exploring DPX-Survivac with low-dose cyclophosphamide and pembrolizumab in selected advanced solid tumors; currently active/no…

• CLINICAL_TRIALS trial_result · 2022-03-24
  Clinical Trial Update: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) [Phase 2]

  Phase 2 pilot study evaluating combined immune checkpoint inhibition with ablative therapies in hepatocellular carcinoma and biliary tract c…

• CLINICAL_TRIALS trial_result · 2022-03-18
  Clinical Trial Update: TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma [NA]

  A terminated early-stage hepatocellular carcinoma trial investigating transarterial embolization (TAE) and microwave ablation (MWA) did not …

• CLINICAL_TRIALS trial_result · 2022-03-16
  Clinical Trial Update: Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma [Phase 2]

  Phase 2 trial evaluating surufatinib alone or with anti-PD-1 monoclonal antibody for advanced hepatocellular carcinoma; status not disclosed…

• CLINICAL_TRIALS trial_result · 2022-02-25
  Clinical Trial Update: Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver [Phase 1, Phase 2]

  Clinical trial evaluating Erlotinib hydrochloride for prevention of liver cancer in patients with cirrhosis; study phases completed with res…

• CLINICAL_TRIALS trial_result · 2022-02-15
  Clinical Trial Update: Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma [Phase 2]

  Phase 2 trial update evaluating adjuvant immunotherapy with toripalimab after curative-intent ablation for recurrent hepatocellular carcinom…

• CLINICAL_TRIALS trial_result · 2022-02-10
  Clinical Trial Update: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. [Phase 3]

  Clinical trial update for SHR-1210 (anti-PD-1) + FOLFOX4 in advanced hepatocellular carcinoma; Phase 3 study with unknown status.

• CLINICAL_TRIALS trial_result · 2022-02-07
  Clinical Trial Update: Accurate Dosimetry and Biomarkers Improve Survival in HCC Patients Treated With Resin 90 Yttrium (90Y)-Microspheres [Phase 2]

  A Phase 2 trial exploring accurate dosimetry and biomarkers for patients with hepatocellular carcinoma treated with resin 90Y microspheres t…